Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kyorin Rejects Sawai's Merger Proprosal, Leaving Japan's Generics Leader Scrambling Ahead Of Big Pharma Competition

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In what amounted to a long-weekend consideration, Kyorin Pharmaceutical has rejected Sawai Pharmaceutical's proposal to initiate merger talks, adding a sense of urgency for the generics manufacturer as it tries to find business solutions to fend off generics competition in Japan from major pharma companies
Advertisement

Related Content

Sawai Pharmaceutical Announces More Structured Proposal For Kyorin Merger, Eyeing Consolidation For Biosimilars In Japan
Sawai Pharmaceutical Announces More Structured Proposal For Kyorin Merger, Eyeing Consolidation For Biosimilars In Japan
Korea's Celltrion And Aprogen In Race To Sell Biosimilars In Japan
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
Advertisement
UsernamePublicRestriction

Register

SC073940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel